Reports
Reports
Annual Drug Utilization Reports
MAPS Drug Utilization Reports offer data regarding controlled substance prescriptions dispensed in Michigan. In 2017, the number of opioid prescriptions dispensed decreased by 10.7 percent since 2015 while the overall number of schedules 2-5 controlled substance prescriptions dispensed decreased by 7.1 percent during that same timespan.
Total CS prescriptions dispensed
% change from previous year
2007
17,007,858
2008
17,400,640
2.31%
2009
17,876,684
2.74%
2010
18,954,172
6.03%
2011
19,763,680
4.27%
2012
20,991,020
6.21%
2013
20,728,216
-1.25%
2014
20,904,764
0.85%
2015
21,472,326
2.71%
2016
21,092,674
-1.77%
2017 19,943,203 -5.45% Select the years below to access individual drug utilization reports.
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
State Opioid Assessment
A new statewide assessment has identified trends that will assist government agencies, lawmakers and local community leaders tailor laws, target resources, and design innovative programs to best address the opioid epidemic in Michigan.
The assessment overlays three years (2013-2015) of well-documented cases of unintentional overdose death with five years (2012-2017) of prescription records in the Michigan Automated Prescription System (MAPS). In total, more than 7.5 million patients receiving 103.2 million prescriptions over the last five years were linked to 5,261 overdose deaths.
The assessment provides valuable information about patterns of opioid usage in Michigan by detailing patient-level and aggregate trends of controlled-substance prescriptions and overdose deaths within the state.
MAPS Resources
Contact MAPS
- Contact Maps Info
Telephone: 517-241-0166
Fax: 517-241-5072
Email: BPL-MAPS@michigan.gov
MAPS Integration
- MAPS Partners
The State of Michigan is covering the full cost of integration of MAPS into the clinical workflow of health systems, physician groups and pharmacies until August 31, 2019. Learn how to start the integration process.
MAPS Legislation
- MAP Legislation Info
If your question(s) pertain to the new opioid legislation, we encourage you to review the recently-released FAQs. Additional questions or concerns can be addressed by contacting MAPS.
- MAPS Partners
- MAPS logo
